Autolus Therapeutics : Corporate Presentation – January 2021

Developing Next

Generation Programmed

T Cell Therapies

January 2022

Developing Next Generation Programmed T Cell Therapies	Autolus.com

Disclaimer

These slides and the accompanying oral presentation contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding Autolus' development of the obe-cel program; the future clinical development, efficacy, safety and therapeutic potential of its product candidates, including progress, expectations as to the reporting of data, conduct and timing and potential future clinical activity and milestones; and expectations regarding the initiation, design and reporting of data from clinical trials. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, the risks that Autolus' preclinical or clinical programs do not advance or result in approved products on a timely or cost effective basis or at all; the results of early clinical trials are not always being predictive of future results; the cost, timing and results of clinical trials; that many product candidates do not become approved drugs on a timely or cost effective basis or at all; the ability to enroll patients in clinical trials; possible safety and efficacy concerns; and the impact of the ongoing COVID-19 pandemic on Autolus' business. For a discussion of other risks and uncertainties, and other important factors, any of which could cause Autolus' actual results to differ from those contained in the forward-looking statements, see the section titled "Risk Factors" in Autolus' Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 4,

2021, as well as discussions of potential risks, uncertainties, and other important factors in Autolus' subsequent filings with the Securities and Exchange Commission. All

information contained herein is as of the date of the presentation, and Autolus undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law. You should, therefore, not rely on these forward-looking statements as representing the Company's views as of any date subsequent to the date of this presentation.

LEAD CLINICAL PROGRAM

obe-cel

For treatment of B-ALL and B-NHL

Developing Next Generation Programmed T Cell Therapies	Autolus.com	4

Driving value with potential best-in-class adult ALL program

Multiple clinical data read-outs in 2022

		Full data for obe-cel
		(FELIX) trial in adult ALL
		expected in 2022
Focused on delivering
obe-cel, a potentially		obe-cel data in B-NHL
transformational treatment	indications in H1 2022
for Adult ALL
		Next generation
		AUTO1/22 data in
		pALL in H1 2022

• Additional value steps in T cell lymphoma and first solid tumor indication in 2022 and 2023
• Broad preclinical pipeline of next generation programs expected
  to transition to clinical stage in 2022
• Building on a scalable, fully enclosed manufacturing platform

Adult Acute Lymphoblastic Leukemia

obe-cel - Potential as a standalone therapy